Targeted attack on stubborn lymphoma shows promise
NCT ID NCT04665765
Summary
This study is testing a new combination of drugs for people with an aggressive type of lymphoma that has returned or not responded to the first treatment. The treatment combines a targeted antibody-drug with standard chemotherapy and immunotherapy. The goal is to see if this combination is safe and effective at controlling the cancer to prepare patients for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.